The BLAZE-1 trial met both primary and key secondary endpoints. Data from a phase 3 trial investigating Lilly’s severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing antibodies, ...

Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. New data from phase 3 trials of monoclonal antibodies for patients with recent COVID-19 diagnoses, ...

Earlier this month, we talked with Daniel Skovronksy, the Chief Scientific Officer of Eli Lilly, about their colorfully-named ...

The U.S. government has stopped its distribution of Eli Lilly’s COVID-19 antibody bamlanivimab alone, saying that the increasing emergence of coronavirus variants has made the treatment ineffective, ...

Bamlanivimab is a recombinant, neutralizing human IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2. It is designed to block viral attachment and entry into human cells, ...

The FDA has extended the shelf life for bamlanivimab, one of two drugs used in Eli Lilly’s monoclonal antibody cocktail treatment, from 18 to 24 months. At present, bamlanivimab and etesevimab — the ...

INDIANAPOLIS, April 16, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) has requested the U.S. Food and Drug Administration (FDA) revoke the Emergency Use Authorization (EUA) for bamlanivimab ...

LOS ANGELES - The U.S. Food and Drug Administration issued an emergency use authorization for Eli Lilly and Company’s monoclonal antibody therapy bamlanivimab to treat mild-to-moderate cases of ...

BOSTON – Monoclonal antibodies are laboratory-designed treatments tailor-made to fight specific infections. In early 2021, the U.S. Food & Drug Administration ...